ATE76747T1 - Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. - Google Patents
Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.Info
- Publication number
- ATE76747T1 ATE76747T1 AT87107979T AT87107979T ATE76747T1 AT E76747 T1 ATE76747 T1 AT E76747T1 AT 87107979 T AT87107979 T AT 87107979T AT 87107979 T AT87107979 T AT 87107979T AT E76747 T1 ATE76747 T1 AT E76747T1
- Authority
- AT
- Austria
- Prior art keywords
- pharmaceutical compositions
- methyl ester
- preparation
- compositions containing
- therapeutic uses
- Prior art date
Links
- 229960001794 melevodopa Drugs 0.000 title abstract 2
- XBBDACCLCFWBSI-ZETCQYMHSA-N melevodopa Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 XBBDACCLCFWBSI-ZETCQYMHSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000001078 anti-cholinergic effect Effects 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 230000003291 dopaminomimetic effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT20737/86A IT1190342B (it) | 1986-06-10 | 1986-06-10 | Composizioni farmaceutiche contenenti levodopa metil estere,loro procedimento di preparazione e relative applicazioni terapeutiche |
| IT19221/87A IT1203321B (it) | 1987-01-30 | 1987-01-30 | Composizioni farmaceutiche contenenti levodora metil estere,loro prodecimento di preparazione e relative applicazioni terapeutiche |
| EP87107979A EP0252290B1 (de) | 1986-06-10 | 1987-06-02 | Levodopa-methyl-ester enthaltende pharmazeutische Zusammensetzungen, ihre Herstellung und therapeutische Verwendungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE76747T1 true ATE76747T1 (de) | 1992-06-15 |
Family
ID=26327098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT87107979T ATE76747T1 (de) | 1986-06-10 | 1987-06-02 | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US4826875A (de) |
| EP (1) | EP0252290B1 (de) |
| JP (1) | JP2572768B2 (de) |
| KR (2) | KR880000092A (de) |
| AT (1) | ATE76747T1 (de) |
| AU (1) | AU605154B2 (de) |
| CA (1) | CA1303509C (de) |
| DE (2) | DE3779500T2 (de) |
| ES (1) | ES2042520T3 (de) |
| GR (1) | GR880300058T1 (de) |
| HU (1) | HUT43952A (de) |
| NZ (1) | NZ220631A (de) |
| PT (1) | PT85055B (de) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4983400A (en) * | 1986-06-16 | 1991-01-08 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| IL92952A (en) * | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| SE9203594D0 (sv) * | 1992-11-30 | 1992-11-30 | Christer Nystroem | Laekemedel i dispersa system |
| US5354885A (en) * | 1992-12-24 | 1994-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Process for preparing ethyl ester of L-DOPA |
| US5607969A (en) * | 1992-12-24 | 1997-03-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | L-DOPA ethyl ester to treat Parkinson's disease |
| DE4325435A1 (de) * | 1993-07-29 | 1995-02-02 | Basf Ag | Neue Wirkstoffkombination |
| IL111240A (en) * | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
| US20050106241A1 (en) * | 1995-02-03 | 2005-05-19 | Brewer Francesca M. | Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase B inhibitors |
| PT814789E (pt) * | 1995-03-02 | 2003-09-30 | Scherer Technologies Inc R P | Composicoes farmaceuticas compreendendo inibidores de monoamina-oxidase b |
| JPH11506744A (ja) | 1995-06-07 | 1999-06-15 | ノウブン ファーマシューティカルズ インク． | 室温で液体である低分子量薬を含む経皮組成物 |
| US6316022B1 (en) | 1995-06-07 | 2001-11-13 | Noven Pharmaceuticals, Inc. | Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
| CN1207675A (zh) * | 1995-11-06 | 1999-02-10 | 萨默塞特药品有限公司 | 丙炔苯丙胺的经颊和舌下给药法 |
| IL119417A (en) * | 1996-10-13 | 2003-02-12 | Moshe Kushnir | Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease |
| PT966435E (pt) | 1996-12-18 | 2005-06-30 | Yissum Res Dev Co | Derivados aminoindano |
| IT1293764B1 (it) * | 1997-07-23 | 1999-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua |
| US20040151768A1 (en) * | 1997-07-23 | 2004-08-05 | Chiesi Farmaceutici S.P.A. | Pharmaceutical compositions containing an effervescent acid-base couple |
| ES2178405T3 (es) * | 1998-03-16 | 2002-12-16 | Somerset Pharmaceuticals Inc | Uso de selegilina o de desmetilselegilina para tratar heridas, quemaduras y lesiones cutaneas. |
| US6376545B1 (en) | 1998-11-10 | 2002-04-23 | Teva Pharmaceutical Industries, Ltd. | Dispersible compositions containing L-DOPA ethyl ester |
| WO2000027801A1 (en) | 1998-11-10 | 2000-05-18 | Teva Pharmaceutical Industries, Ltd. | Process for manufacture of l-dopa ethyl ester |
| US6506378B1 (en) | 1998-12-16 | 2003-01-14 | Arch Development Corporation | Vesicular monoamine transporter gene therapy in Parkinson's disease |
| US6737547B1 (en) | 1998-12-31 | 2004-05-18 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using N-acyl-1H-aminoindenes |
| AU2001296703A1 (en) * | 2000-10-06 | 2002-04-15 | Xenoport, Inc. | Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism |
| US20040010038A1 (en) * | 2002-02-27 | 2004-01-15 | Eran Blaugrund | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors |
| US8338420B1 (en) | 2002-12-04 | 2012-12-25 | Mitsubishi Tanabe Pharma Corporation | Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor |
| AU2003293423A1 (en) | 2002-12-06 | 2004-06-30 | Xenoport, Inc. | Carbidopa prodrugs and uses thereof |
| DE10261807A1 (de) * | 2002-12-19 | 2004-07-01 | Turicum Drug Development Ag | Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel |
| AR044007A1 (es) | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| CA2523567A1 (en) * | 2003-04-25 | 2004-11-11 | Indevus Pharmaceuticals, Inc. | Method for promoting uninterrupted sleep by administration of trospium chloride |
| US8815950B2 (en) | 2003-08-29 | 2014-08-26 | Janssen Biotech, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| CA2536175C (en) * | 2003-08-29 | 2013-05-28 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| US20050113452A1 (en) * | 2003-10-20 | 2005-05-26 | Moshe Flashner-Barak | Composition and dosage form for sustained effect of levodopa |
| US7576073B2 (en) * | 2004-05-28 | 2009-08-18 | UNIVERSITé LAVAL | Combined therapy for the treatment of parkinson's disease |
| WO2005121070A1 (en) * | 2004-06-04 | 2005-12-22 | Xenoport, Inc. | Levodopa prodrugs, and compositions and uses thereof |
| JP4781352B2 (ja) * | 2004-06-04 | 2011-09-28 | ゼノポート，インコーポレーテッド | レボドパプロドラッグおよびその組成物ならびにその使用 |
| SE0401842D0 (sv) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| US20060173074A1 (en) | 2004-11-10 | 2006-08-03 | Juha Ellmen | Treatment of restless legs syndrome |
| US20070148238A1 (en) * | 2005-06-23 | 2007-06-28 | Spherics, Inc. | Dosage forms for movement disorder treatment |
| US20080300204A1 (en) * | 2005-07-19 | 2008-12-04 | University Of Rochester | Alpha-Synuclein Antibodies and Methods Related Thereto |
| AU2006322051B2 (en) * | 2005-12-05 | 2011-09-29 | Xenoport, Inc. | Levodopa prodrug mesylate, compositions thereof, and uses thereof |
| EP1956904B1 (de) * | 2005-12-09 | 2017-04-12 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Niedrig dosierter ladostigil zur behandlung von leichter kognitiver beeinträchtigung |
| HUE028777T2 (en) * | 2006-02-17 | 2017-01-30 | Ratiopharm Gmbh | Deuterated catecholamine derivatives and medicaments containing these compounds |
| TW200744576A (en) * | 2006-02-24 | 2007-12-16 | Teva Pharma | Propargylated aminoindans, processes for preparation, and uses thereof |
| US20080131492A1 (en) * | 2006-06-23 | 2008-06-05 | Spherics, Inc. | Dosage forms for movement disorder treatment |
| TW200843731A (en) * | 2006-12-21 | 2008-11-16 | Xenoport Inc | Catechol protected levodopa diester prodrugs, compositions, and methods of use |
| US7709527B2 (en) * | 2006-12-21 | 2010-05-04 | Xenoport, Inc. | Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use |
| EP2063867A2 (de) * | 2006-12-22 | 2009-06-03 | Combinatorx, Incorporated | Pharmazeutische zusammensetzungen zur behandlung von morbus parkinson und damit verbundenen leiden |
| CN105581999A (zh) | 2007-02-06 | 2016-05-18 | 安元有限公司 | 用于抑制神经传导的包括萜烯化合物的组合物以及方法 |
| US20090143388A1 (en) * | 2007-08-29 | 2009-06-04 | Mohanakumar Kochupurackal Para | Treatment of brain disorders |
| CN101283965B (zh) * | 2007-10-26 | 2010-06-16 | 南京长澳医药科技有限公司 | 一种含左旋多巴甲酯的制剂及制备方法 |
| KR101451564B1 (ko) | 2007-12-28 | 2014-11-04 | 임팩스 라보라토리즈, 인코포레이티드 | 레보도파 방출 제어형 제제 및 이의 용도 |
| US9415023B2 (en) | 2008-08-13 | 2016-08-16 | Neuroquest Inc. | Compositions comprising terpene compounds for treating negative sensory phenomena |
| US8399513B2 (en) | 2008-10-20 | 2013-03-19 | Xenoport, Inc. | Levodopa prodrug mesylate hydrate |
| EP2349973A2 (de) * | 2008-10-20 | 2011-08-03 | XenoPort, Inc. | Verfahren zur synthese einer levodopa ester-prodrug |
| US8286311B2 (en) | 2008-10-31 | 2012-10-16 | Jisook Paik | Buckle |
| EP2421367A4 (de) * | 2009-04-23 | 2012-05-23 | Univ Cincinnati | Verabreichung von allantoin zur behandlung von neurodegenerativen erkrankungen und neurotrauma |
| SG10201505101VA (en) * | 2009-05-19 | 2015-07-30 | Neuroderm Ltd | Compositions For Continuous Administration Of Dopa Decarboxylase Inhibitors |
| JP2013520521A (ja) | 2009-11-09 | 2013-06-06 | ゼノポート，インコーポレーテッド | レボドパプロドラッグの医薬組成物及び経口剤形並びに使用方法 |
| KR101196354B1 (ko) | 2010-09-03 | 2012-11-01 | 서유헌 | 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물 |
| SI2640358T1 (en) | 2010-11-15 | 2018-05-31 | Neuroderm Ltd. | Continuous administration of L-dopa, dopamine decarboxylase inhibitors, catechol-O-methyl transferase inhibitors, and compositions thereof |
| SG191090A1 (en) * | 2010-12-10 | 2013-07-31 | Synagile Corp | Subcutaneously infusible levodopa prodrug compositions and methods of infusion |
| AU2013273138B2 (en) | 2012-06-05 | 2017-06-15 | Neuroderm Ltd | Compositions comprising apomorphine and organic acids and uses thereof |
| WO2014164730A2 (en) | 2013-03-12 | 2014-10-09 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of cellular dna repair activity to intercept malignancy |
| CN105209039B (zh) | 2013-03-15 | 2018-06-22 | 百时美施贵宝公司 | Lxr调节剂 |
| ES2694001T3 (es) | 2013-03-15 | 2018-12-17 | Bristol-Myers Squibb Company | Moduladores de LXR |
| WO2015027431A1 (en) | 2013-08-29 | 2015-03-05 | Merck Sharp & Dohme Corp. | 2,2-difluorodioxolo a2a receptor antagonists |
| US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| JP6506271B2 (ja) * | 2013-10-07 | 2019-04-24 | インパックス ラボラトリーズ、 インコーポレイテッドＩｍｐａｘ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． | レボドパ及び／又はレボドパのエステルの粘膜付着性制御放出配合物、並びにその使用 |
| WO2015136538A1 (en) | 2014-03-13 | 2015-09-17 | Neuroderm Ltd | Dopa decarboxylase inhibitor compositions |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| WO2016179540A1 (en) | 2015-05-06 | 2016-11-10 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| US11844860B2 (en) | 2018-03-02 | 2023-12-19 | Chiesi Farmaceutici S.P.A. | Pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
| WO2022140448A1 (en) | 2020-12-22 | 2022-06-30 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
| WO2025075499A1 (en) | 2023-10-02 | 2025-04-10 | Universiteit Van Amsterdam | Reducing dopamine feed-back inhibition in dopaminergic cells by tadalafil. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3787581A (en) * | 1970-03-24 | 1974-01-22 | M Sandler | Pharmaceutical compositions and methods of treatment |
| JPS5157813A (en) * | 1974-11-14 | 1976-05-20 | Sankyo Co | Ll dooba mataha sonojudotaiseizaino seiho |
| US4663349A (en) * | 1985-12-30 | 1987-05-05 | Merck & Co., Inc. | Rectally absorbable form of L-dopa |
-
1987
- 1987-06-02 EP EP87107979A patent/EP0252290B1/de not_active Expired - Lifetime
- 1987-06-02 ES ES87107979T patent/ES2042520T3/es not_active Expired - Lifetime
- 1987-06-02 DE DE8787107979T patent/DE3779500T2/de not_active Expired - Lifetime
- 1987-06-02 AT AT87107979T patent/ATE76747T1/de not_active IP Right Cessation
- 1987-06-02 DE DE198787107979T patent/DE252290T1/de active Pending
- 1987-06-08 AU AU74053/87A patent/AU605154B2/en not_active Expired
- 1987-06-09 CA CA000539220A patent/CA1303509C/en not_active Expired - Lifetime
- 1987-06-09 NZ NZ220631A patent/NZ220631A/en unknown
- 1987-06-09 PT PT85055A patent/PT85055B/pt not_active IP Right Cessation
- 1987-06-09 JP JP62143959A patent/JP2572768B2/ja not_active Expired - Lifetime
- 1987-06-09 KR KR870005806A patent/KR880000092A/ko not_active Withdrawn
- 1987-06-09 HU HU872628A patent/HUT43952A/hu unknown
- 1987-07-21 KR KR1019870007874A patent/KR950002150B1/ko not_active Expired - Lifetime
- 1987-11-20 US US07/123,118 patent/US4826875A/en not_active Expired - Lifetime
-
1988
- 1988-05-20 GR GR88300058T patent/GR880300058T1/el unknown
-
1989
- 1989-06-30 US US07/374,273 patent/US5017607A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0252290A3 (en) | 1990-01-24 |
| DE3779500T2 (de) | 1993-01-21 |
| AU605154B2 (en) | 1991-01-10 |
| DE252290T1 (de) | 1988-06-09 |
| JP2572768B2 (ja) | 1997-01-16 |
| ES2042520T3 (es) | 1993-12-16 |
| AU7405387A (en) | 1987-12-17 |
| US5017607A (en) | 1991-05-21 |
| CA1303509C (en) | 1992-06-16 |
| DE3779500D1 (de) | 1992-07-09 |
| EP0252290A2 (de) | 1988-01-13 |
| EP0252290B1 (de) | 1992-06-03 |
| US4826875A (en) | 1989-05-02 |
| KR880000092A (ko) | 1988-03-23 |
| HUT43952A (en) | 1988-01-28 |
| JPS6327428A (ja) | 1988-02-05 |
| PT85055A (pt) | 1988-07-01 |
| NZ220631A (en) | 1990-12-21 |
| PT85055B (pt) | 1994-10-31 |
| KR950002150B1 (ko) | 1995-03-14 |
| KR890001533A (ko) | 1989-03-27 |
| GR880300058T1 (en) | 1988-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE76747T1 (de) | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. | |
| DE3686483D1 (de) | Arzneimittel. | |
| NO166448C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner. | |
| DE69223914D1 (de) | 4-substituierte-2-Deoxy-2,3-Didehydro Alpha-D-Neuraminsäure antivirale Derivate | |
| ES2052717T3 (es) | Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson. | |
| NO904986L (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive diazepin-derivater. | |
| PT615754E (pt) | Formas solidas de administracao oral de libertacao controlada flupertina | |
| FR2711140B1 (fr) | 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant. | |
| DK0412554T3 (da) | Sustained-release-præparat til administration i hjernen | |
| SE8404065D0 (sv) | Novel biologically active compounds | |
| DK0629400T3 (da) | Idebenon-holdige præparater til behandling af Alzheimer's syge | |
| NO165071C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 7-(3-amino-1-pyrrolidinyl)-8-klor-1-cyklopropyl-6- fluor-1,4,-dihydro-4-okso-3-kinolin-karboksylsyre. | |
| NO900697D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive acetamid-derivater. | |
| ATE334590T1 (de) | Anti-arrhythmische zusammensetzungen und behandlungsverfahren | |
| FR2707638B1 (fr) | Nouveaux dérivés d'amino-acides, leurs procédés de préparation et leur application thérapeutique. | |
| HUP9802897A3 (en) | Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient | |
| KR900009029A (ko) | 가축병 치료용 약물을 투여하는 장치 | |
| NO172491C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksan-alkensyre-dervater | |
| NO167801C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,2'-bi-1h-imidazolderivater. | |
| SE8802323D0 (sv) | 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it | |
| TH14574A (th) | สารผสมทางเภสัชกรรม | |
| UA30143A (uk) | Лікувальний препарат для профілактики та лікування інфекційних та запальних захворювань | |
| NO164651C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive aminofenol-derivater. | |
| NO168106C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive estere av hexahydro-8-hydroxy-2,6-methano-2h-kinolizin-3(4h)-on | |
| IT1238210B (it) | Esteri del cefamandolo nafato, procedimento per la loro preparazione erelative composizioni farmaceutiche. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| EELA | Cancelled due to lapse of time |